A share price of Kymera Therapeutics Inc [KYMR] is currently trading at $43.56, up 8.57%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KYMR shares have gain 6.45% over the last week, with a monthly amount glided 3.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on December 10, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $60. Previously, BMO Capital Markets started tracking the stock with Market Perform rating on December 06, 2024, and set its price target to $55. On December 02, 2024, upgrade upgraded it’s rating to Overweight but maintained its price target of $57 on the stock. Stephens started tracking the stock assigning a Overweight rating and suggested a price target of $65 on November 18, 2024. Wolfe Research upgraded its rating to Outperform for this stock on August 26, 2024, but kept the price target unchanged to $65. In a note dated April 22, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $53 on this stock.
Kymera Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $26.34 and $53.27. Currently, Wall Street analysts expect the stock to reach $58.6 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $43.56 at the most recent close of the market. An investor can expect a potential return of 34.53% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Trailing Twelve Months sales for Kymera Therapeutics Inc [NASDAQ:KYMR] were 87.56M which represents -20.88% decline. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -2.23%, Pretax Profit Margin comes in at -1.91%, and Net Profit Margin reading is -1.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.25 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.45 points at the first support level, and at 39.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.01, and for the 2nd resistance point, it is at 46.45.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kymera Therapeutics Inc [NASDAQ:KYMR] is 8.55. As well, the Quick Ratio is 8.55, while the Cash Ratio is 1.66. Considering the valuation of this stock, the price to sales ratio is 32.22, the price to book ratio is 3.16.
Transactions by insiders
Recent insider trading involved Chiniara Ellen, Chief Legal Officer, that happened on Jan 06 ’25 when 3129.0 shares were sold. Officer, Chiniara Ellen completed a deal on Jan 06 ’25 to buy 3129.0 shares. Meanwhile, Director Esposito Pamela sold 2500.0 shares on Dec 02 ’24.
